News

Odaily Seer monitoring shows that a newly created address on Polymarket bought $7,500 worth of Hunter Biden to become the 2028 Democratic presidential candidate, with an average purchase price of 0.7¢. Possibly influenced by this, several wallets followed suit and bought in, pushing the probability from 0.7% up to the current 2.9%. Reportedly, Hunter Biden is the second son of Joe Biden, the 46th President of the United States, and is his only surviving son. Related controversies have run throughout President Biden's term, becoming a core weapon for the Republican Party to attack the Biden administration for "corruption" and "nepotism". Odaily Seer continues to monitor prediction markets, seeing changes before pricing occurs.

According to Odaily, monitoring by Lookonchain shows that loracle.hl (@loraclexyz) previously lost $46.46 million shorting HYPE and then switched to going long on HYPE, currently losing another $840,000.

Glonghui, June 5th｜Citi pointed out that investor concerns about abnormal sensations associated with Eli Lilly’s experimental weight-loss drug retatrutide are “somewhat overblown," and added that this signal "does exist, but is of little consequence in the specific context." In recent late-stage clinical data, patients receiving the highest dose of retatrutide lost about 28% of their weight within 80 weeks, with approximately 12.5% of patients in this group experiencing abnormal sensations. Most cases in the late-stage study were mild to moderate, resolved on their own during treatment, and rarely led to discontinuation. The bank also added that this issue is not a risk unique to retatrutide, but a known class effect among other weight-loss medications. Citi stated that more data will be released at the upcoming diabetes conference, which may further highlight the differences between retatrutide and marketed products, and support its wider adoption. The bank reiterated its “Buy” rating on Eli Lilly, with a target price of $1,500.